Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee ap
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks